Immunodeficiency
Primary immunodeficiencies (PIDs) are a group of more than 400 potentially serious disorders that can lead to frequent or severe infections, swellings and autoimmune problems. PIDs can be caused by defects in the genes that control the immune system, and may be inherited.
Information for Patients, Consumers and Carers
ASCIA COVID-19 information for patients, consumers, carers https://allergy.org.au/patients/covid-19
-
COVID-19 Frequently Asked Questions (FAQ) Updated May 2020
- Checklist: Actions to reduce the spread of COVID-19 Updated May 2020
-
COVID-19 and Immunodeficiency Updated May 2020 (Accessed more than 94,000 times in March and April 2020)
- COVID-19, Immunodeficiency and School Attendance New May 2020
SCIg therapy - general information for patients and carers
Common variable immunodeficiency (CVID)
Immunoglobulin replacement therapy (IRT)
Primary immunodeficiency (PIDs)
Severe combined immunodeficiency (SCID)
Hereditary angiodema (HAE) - under development
Subcutaneous Immunogobulin (SCIg) Information
SCIg therapy - general information for patients and carers
SCIg information handouts for patients and carers (ASCIA member access only)
Guide - Setting up a SCIg service in a hospital
Transfer Care Plan for patients on IRT (immunoglobulin replacement therapy)
Travel Plan for patients on SCIg (subcutaneous immunoglobulin) therapy
Other Information for Health Professionals
ASCIA COVID-19 information for health professionals www.allergy.org.au/hp/papers#covid
- ASCIA Position Statement - Specific Treatments for COVID-19 New April 2020
- ASCIA Position Statement - Immunoglobulin Therapies for COVID-19 New April 2020
- ASCIA Webinar - Part 1: HAE. Part 2: COVID-19 New April 2020
Guidelines – Standardised infusion rates for intravenous immunoglobulin (IVIg) replacement therapy
Primary immunodeficiencies (PID) Clinical Update
Primary immunodeficiencies (PID) e-training e-training
Hereditary Angioedema (HAE) Position Paper and Management Plan
Content updated May 2020
